Literature DB >> 25757362

Interleukin-10 levels in rat models of nerve damage and neuropathic pain.

Junad Khan1, Khaled Ramadan2, Olga Korczeniewska2, Muhammad Moin Anwer2, Rafael Benoliel3, Eli Eliav4.   

Abstract

Interleukin-10 (IL-10) is an anti-inflammatory cytokine that has been shown to play a role in inflammatory and autoimmune disorders as well as in neuropathic pain conditions. The objective of the present study was to assess the levels of IL-10 in rat's dorsal root ganglion (DRG) and the sciatic nerve following four different forms of sciatic nerve injury. The models used to induce the injury included two models of partial nerve injury: partial sciatic ligation (PSL) and chronic constriction injury (CCI), a model of complete sciatic transection (CST) and a model of perineural inflammation with minimal nerve damage (neuritis). Withdrawal responses for mechanical stimulus and withdrawal latency for thermal stimulation were used to measure mechanical and thermal hyperalgesia, respectively, and duration of the nociceptive withdrawal reflex to mechanical stimulus was used to measure mechanical hyperalgesia. The affected and contra-lateral nerves and the affected side DRG IL-10 levels were assessed by the means of enzyme-linked immunosorbent assay (ELISA), 3 and 8 days following the procedure and were compared to naïve rats' IL-10 levels. The rats exposed to CCI and neuritis developed significant mechanical and thermal hyperalgesia as well as mechanical hyperalgesia 3 and 8 days following the surgical procedure. Rats exposed to CST did not respond to mechanical stimulation and developed thermal hypoalgesia 3 and 8 days after the surgery. The DRG IL-10 levels were significantly reduced 3 and 8 days following CCI and PSL, significantly increased 3 and 8 days following CST, and remained unchanged following neuritis. The sciatic nerve IL-10 levels reduced significantly in both injured and contra-lateral nerves 3 and 8 days following CCI and PSL, elevated significantly in the injured but not in the contra-lateral nerve 3 and 8 days following CST and remained unchanged following neuritis. The results of this study suggest that IL-10's role in the neuropathic pain etiology may be specific to nerve injury type. Complete nerve transection increases while partial nerve injury reduces IL-10 levels in the involved nerve, and DRG. Perineural inflammation with minimal nerve damage has no effect on IL-10 levels.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Interleukin-10; Nerve damage; Neuritis; Neuropathic pain

Mesh:

Substances:

Year:  2015        PMID: 25757362     DOI: 10.1016/j.neulet.2015.03.001

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

Review 1.  Targeting cytokines for treatment of neuropathic pain.

Authors:  Alice L Hung; Michael Lim; Tina L Doshi
Journal:  Scand J Pain       Date:  2017-08-24

2.  Bupivacaine effectively relieves inflammation-induced pain by suppressing activation of the NF-κB signalling pathway and inhibiting the activation of spinal microglia and astrocytes.

Authors:  Jingliang Zhang; Xinlian Deng
Journal:  Exp Ther Med       Date:  2017-01-18       Impact factor: 2.447

3.  Adenosine A3 agonists reverse neuropathic pain via T cell-mediated production of IL-10.

Authors:  Mariaconcetta Durante; Silvia Squillace; Filomena Lauro; Luigino Antonio Giancotti; Elisabetta Coppi; Federica Cherchi; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Grant Kolar; Carrie Wahlman; Adeleye Opejin; Cuiying Xiao; Marc L Reitman; Dilip K Tosh; Daniel Hawiger; Kenneth A Jacobson; Daniela Salvemini
Journal:  J Clin Invest       Date:  2021-04-01       Impact factor: 14.808

4.  Effects of spinal non-viral interleukin-10 gene therapy formulated with d-mannose in neuropathic interleukin-10 deficient mice: Behavioral characterization, mRNA and protein analysis in pain relevant tissues.

Authors:  Arden G Vanderwall; Shahani Noor; Melody S Sun; Jacob E Sanchez; Xuexian O Yang; Lauren L Jantzie; Nikolaos Mellios; Erin D Milligan
Journal:  Brain Behav Immun       Date:  2017-11-04       Impact factor: 7.217

5.  Whole Genomic DNA Methylation Profiling of CpG Sites in Promoter Regions of Dorsal Root Ganglion in Diabetic Neuropathic Pain Mice.

Authors:  Wen Chen; Ting Lan; Qingyu Sun; Yurui Zhang; Danmin Shen; Tingting Hu; Jing Liu; Yingzi Chong; Peipei Wang; Qian Li; Weihua Cui; Fei Yang
Journal:  J Mol Neurosci       Date:  2021-05-05       Impact factor: 3.444

6.  Presence of caffeine reversibly interferes with efficacy of acupuncture-induced analgesia.

Authors:  Takumi Fujita; Changyong Feng; Takahiro Takano
Journal:  Sci Rep       Date:  2017-06-13       Impact factor: 4.379

7.  Saikosaponin a increases interleukin-10 expression and inhibits scar formation after sciatic nerve injury.

Authors:  Meng-Qiang Huang; Xiao-Yu Cao; Xu-Yi Chen; Ying-Fu Liu; Shuang-Long Zhu; Zhong-Lei Sun; Xian-Bin Kong; Jing-Rui Huo; Sai Zhang; Yun-Qiang Xu
Journal:  Neural Regen Res       Date:  2018-09       Impact factor: 5.135

8.  Targeting the β2-integrin LFA-1, reduces adverse neuroimmune actions in neuropathic susceptibility caused by prenatal alcohol exposure.

Authors:  Joshua J Sanchez; Jacob E Sanchez; Shahani Noor; Chaselyn D Ruffaner-Hanson; Suzy Davies; Carston R Wagner; Lauren L Jantzie; Nikolaos Mellios; Daniel D Savage; Erin D Milligan
Journal:  Acta Neuropathol Commun       Date:  2019-04-08       Impact factor: 7.801

9.  The Elevated Serum Level of IFN-γ in Patients with Failed Back Surgery Syndrome Remains Unchanged after Spinal Cord Stimulation.

Authors:  Piotr Kamieniak; Joanna Bielewicz; Cezary Grochowski; Jakub Litak; Agnieszka Bojarska-Junak; Beata Daniluk; Tomasz Trojanowski
Journal:  Dis Markers       Date:  2019-01-14       Impact factor: 3.434

10.  LFA-1 antagonist (BIRT377) similarly reverses peripheral neuropathic pain in male and female mice with underlying sex divergent peripheral immune proinflammatory phenotypes.

Authors:  Shahani Noor; Melody S Sun; Arden G Vanderwall; Mara A Havard; Jacob E Sanchez; Nathan W Harris; Monique V Nysus; Jeffrey P Norenberg; Harrison T West; Carsten R Wagner; Lauren L Jantzie; Nikolaos Mellios; Erin D Milligan
Journal:  Neuroimmunol Neuroinflamm       Date:  2019-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.